Guest Editors
Dr. Laura Croft
Queensland University of Technology, Faculty of Health, School of Biomedical Sciences, Centre for Genomics and Personalised Health
Dr. Croft completed her PhD degree at Griffith University, Brisbane, Australia. She held a post-doctoral position at the Queensland Institute of Medical Research, where she studied selenium biology and metabolism, redox regulation of protein function and selenoprotein translation. In 2012, Laura joined the Cancer and Ageing Research Program at Queensland University of Technology. Laura’s research focuses on targeting DNA repair proteins using oligonucleotides and translating basic research into cancer therapeutics. In 2019 Laura was awarded the Advance Queensland Industry Research Fellowship to continue the development of a lead oligonucleotide through toxicology studies and towards first-in-human trials. Laura is a member of the Oligonucleotide Therapeutics Society (OTS) and is actively involved in science education at community events.
Dr. Patrick Thomas
Queensland Bladder Cancer Initiative, Queensland University of Technology, Faculty of Health, School of Biomedical Sciences
Dr. Patrick Thomas completed his PhD in the field of prostate cancer research at Queensland University of Technology. In 2018, Dr. Thomas joined the Queensland Bladder Cancer Initiative where his research is focused on developing patient-derived organoid and immuno-oncology personalised medicine pipelines to improve treatment outcomes in urological tumours. Patrick holds posts as a lecturer at the University of Southern Queensland and as a Director for Prostate Awareness Australia (PAA).
Collection Overview
3D spheroid cultures and patient derived organoids (PDOs) have emerged as superior models for supporting predictive drug screening and personalized medicine. 3D models effectively recapitulate the spectrum of clinical tumors, and offer improved mechanical properties, viability, drug metabolism and secretion compared with those of 2D cultures. The enhanced recapitulation of the native tumour microenvironment makes these a more suitable approach for assessing therapeutic response. This methods collection highlights protocols to establish 3D cell culture models (including spheroid and PDO models) from multiple tumor types for predictive drug testing. Included will be detailed methods describing the practical establishment of organoid cultures from tumor specimens obtained from surgical procedures, and strategies to determine the evaluation of 3D cultures i.e., response to drug testing, imaging, and investigations of 3D biology in vitro. A collection of methods surmising 3D tumor replicate models is timely, given the increasing pace of personalized medicine. There is a need to develop and standardize the most promising laboratory methodologies of 3D cancer cultures to move towards a better stratification of effective cancer therapies.
Articles
Culture of Bladder Cancer Organoids as Precision Medicine Tools
0 Views
•
Cited by 4
•
2021
•
Patrick B. Thomas1,2,3,4, Mahasha P. J. Perera1,2,3,4,5, Saeid Alinezhad1,4, Andre Joshi1,4,5, Paria Saadat1,2, Clarissa Nicholls1,2, Caitlin P. Devonport1,2,4, Alivia R. Calabrese1,2,3,4, Abby R. Templeton1,2,3, Jack R. Wood1,2, Nathan J. Mackenzie1,2, Penny L. Jeffery1,2,3,4, Ian Vela*1,2,3,4,5, Elizabeth D. Williams*1,2,3,4
1School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT) at Translational Research Institute, 2Queensland Bladder Cancer Initiative (QBCI), 3Centre for Personalised Analysis of Cancers (CPAC), 4Australian Prostate Cancer Research Centre - Queensland, 5Department of Urology, Princess Alexandra Hospital
Rapid Optical Clearing for Semi-High-Throughput Analysis of Tumor Spheroids
0 Views
•
Cited by 2
•
2022
•